These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11098880)

  • 21. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric obsessive-compulsive disorder: an update for advanced practice psychiatric nurses.
    Kameg KM; Richardson L; Szpak JL
    J Child Adolesc Psychiatr Nurs; 2015 May; 28(2):84-91. PubMed ID: 25950460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obsessive-compulsive disorder in children and adolescents.
    Krebs G; Heyman I
    Arch Dis Child; 2015 May; 100(5):495-9. PubMed ID: 25398447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obsessive-compulsive disorder in elderly patients.
    Jackson CW
    Drugs Aging; 1995 Dec; 7(6):438-48. PubMed ID: 8601051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia.
    Tibbo P; Gendemann K
    Can J Psychiatry; 1999 Dec; 44(10):1049-50. PubMed ID: 10637686
    [No Abstract]   [Full Text] [Related]  

  • 27. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Obsessive-compulsive disorder and schizophrenia].
    Denda K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):459-63. PubMed ID: 12877026
    [No Abstract]   [Full Text] [Related]  

  • 29. Relationship between obsessive-compulsive disorder and chaos.
    Kubota S; Sakai K
    Med Hypotheses; 2002 Jul; 59(1):16-23. PubMed ID: 12160676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of clomipramine in obsessive-compulsive disorder.
    Howland RH
    Anxiety; 1996; 2(1):56-7. PubMed ID: 9160602
    [No Abstract]   [Full Text] [Related]  

  • 32. Exploring the minimal important difference in the treatment of paediatric obsessive-compulsive disorder using selective serotonin reuptake inhibitors.
    Cohen SE; Denys DAJP; Mattila TK; Storosum BWC; de Boer A; Zantvoord JB
    BMJ Ment Health; 2024 Jun; 27(1):. PubMed ID: 38901870
    [No Abstract]   [Full Text] [Related]  

  • 33. [Physiopathology of obsessive-compulsive disorder--special reference to aspects of the neurochemistry].
    Seishin Shinkeigaku Zasshi; 2009; 111(7):796-801. PubMed ID: 19999279
    [No Abstract]   [Full Text] [Related]  

  • 34. Non-selective effects of selective serotonin reuptake inhibitors.
    Zurowski B; Kordon A; Wahl K; Hohagen F
    Biol Psychiatry; 2008 Jan; 63(1):e5; author reply e7. PubMed ID: 17693390
    [No Abstract]   [Full Text] [Related]  

  • 35. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence.
    Hammerness PG; Vivas FM; Geller DA
    J Pediatr; 2006 Feb; 148(2):158-65. PubMed ID: 16492422
    [No Abstract]   [Full Text] [Related]  

  • 36. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
    Williams K; Brignell A; Randall M; Silove N; Hazell P
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004677. PubMed ID: 23959778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Hazari N; Narayanaswamy JC; Arumugham SS
    Expert Rev Neurother; 2016 Oct; 16(10):1175-91. PubMed ID: 27282021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period.
    Brakoulias V; Viswasam K; Dwyer A; Raine KH; Starcevic V
    Expert Opin Pharmacother; 2020 Feb; 21(2):163-165. PubMed ID: 31893946
    [No Abstract]   [Full Text] [Related]  

  • 40. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.